XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.
S
S

Sanofi

뉴스

Reuters - 4 시간 전

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch July 16 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. EUROFINS EUFI.PA The Luxembourg-based firm on Monday said it opposed the decision by its competitor SGS to call off a planned sale of its crop science unit.
E
L
S
S
F
N
U
Reuters - 23 시간 전

Danone expects Olympics sales boost after revamping brands ahead of Games

Danone expects Olympics sales boost after revamping brands ahead of Games By Richa Naidu LONDON, July 15 (Reuters) - Olympics sponsor Danone DANO.PA is expecting both a short and longer-term sales boost from the Games, having made changes to its products, invested in branding, and positioned itself in physical kiosks across Paris, its CEO said. Danone, which makes Activia yoghurt, Evian water and Silk plant-based drinks, first reached out to the International Olympic Committee in mid-2022 to get
D
L
S
C
Reuters - 4 일 전

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market

UPDATE 1-Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market Adds response from Shaheen's office in paragraph 5 By Maggie Fick and Ahmed Aboulenein LONDON/WASHINGTON, July 12 (Reuters) - Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
S
Reuters - 4 일 전

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market By Maggie Fick and Ahmed Aboulenein LONDON/WASHINGTON, July 12 (Reuters) - Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
S
Reuters - 4 일 전

Banks Plan 6 Billion Euro Debt Financing For Sanofi Consumer Sale- Bloomberg News

BRIEF-Banks Plan 6 Billion Euro Debt Financing For Sanofi Consumer Sale- Bloomberg News July 12 (Reuters) - BANKS PLAN €6 BILLION DEBT FINANCING FOR SANOFI CONSUMER SALE- BLOOMBERG NEWS Source https://tinyurl.com/yc8rv8bh
B
G
S
Reuters - 4 일 전

EMA's PRAC Says Could Not Establish A Causal Association Between 1 Analogues And Aspiration

BRIEF-EMA's PRAC Says Could Not Establish A Causal Association Between GLP-1 Analogues And Aspiration July 12 (Reuters) - EMA's PRAC: EMA'S PRAC: NEW RECOMMENDATIONS FOR GLP-1 RECEPTOR AGONISTS TO MINIMISE RISK OF ASPIRATION & PNEUMONIA ASPIRATION IN GENERAL ANAESTHESIA/DEEP SEDATION EMA'S PRAC: PATIENTS TREATED WITH GLP-1 MEDICINES SHOULD INFORM T
A
S
Reuters - 5 일 전

US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices

UPDATE 1-US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices Adds Novo Nordisk's responses in paragraphs 6-7 and 22 By Ahmed Aboulenein WASHINGTON, July 10 (Reuters) - Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk NOVOb.CO can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy drugs used for weight loss by publicly shaming the company over how much it charges compared with prices in other countries.
S
Reuters - 6 일 전

Sanofi Ships U.S. Influenza Vaccines For The 2024/25 Season

BRIEF-Sanofi Ships U.S. Influenza Vaccines For The 2024/25 Season Sanofi SA SASY.PA : SANOFI SHIPS U.S. INFLUENZA VACCINES FOR THE 2024/25 SEASON SANOFI - ADDITIONAL SHIPMENTS OF FULL SANOFI FLU VACCINE PORTFOLIO WILL CONTINUE THROUGH OCTOBER Source text for Eikon: ID:nPn6wmY2Pa Further company coverage: SASY.PA
S
Reuters - 6 일 전

CVS Health, Cigna down after report FTC to sue PBMs over insulin prices

BUZZ-CVS Health, Cigna down after report FTC to sue PBMs over insulin prices ** Shares of health insurers fall; CVS Health CVS.N down ~1% at $57.05 and Cigna CI.N slips 0.8% to $325.88 ** The U.S. Federal Trade Commission (FTC) plans to sue pharmacy-benefit managers (PBMs) CVS Health, Cigna and UnitedHealth UNH.N , a source familiar with the matter told Reuters ** The FTC is suing the companies over their tactics for negotiating prices for drugs, including insulin - source ** The FTC is also loo
C
S
Reuters - 6 일 전

US FTC to sue drug middlemen over insulin prices, source says

UPDATE 5-US FTC to sue drug middlemen over insulin prices, source says Adds Novo declining comment, background on insulin By Jody Godoy and Mariam Sunny July 10 (Reuters) - The U.S. Federal Trade Commission is planning to sue UnitedHealth UNH.N , Cigna CI.N and CVS Health CVS.N over their tactics as middlemen in negotiating prices for drugs including insulin, a person familiar with the matter s aid on Wednesday.
C
S
Reuters - 1 주 전

Kymera rises, partner Sanofi to expand trials for inflammatory disease drug

BUZZ-Kymera rises, partner Sanofi to expand trials for inflammatory disease drug ** Shares of Kymera Therapeutics KYMR.O up 12.6% at $36 after the bell ** The drug developer says partner Sanofi SASY.PA plans to expand ongoing mid-stage studies for experimental drug to treat Hidradenitis Suppurativa, a chronic inflammatory skin condition, and Atopic
S
Reuters - 1 주 전

Pharma partnerships brewing for assisted drug discovery efforts, Jefferies says

BUZZ-Pharma partnerships brewing for AI-assisted drug discovery efforts, Jefferies says ** Pharma companies are accelerating partnerships across AI landscape to start "leveraging early innings of AI-assisted drug discovery efforts" - brokerage Jefferies ** AI may have power to improve success, reduce risk and lower costs in drug development in the
S
Reuters - 2 주 전

Bpifrance eyes investment in Sanofi's consumer health business

Bpifrance eyes investment in Sanofi's consumer health business July 4 (Reuters) - Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's SASY.PA consumer health unit, Bloomberg News reported on Thursday. The French public investment bank is in talks with "many funds" and may team up with the winning bidder for Sanofi's consumer health unit, Gonzalo was quoted as saying.
S
Reuters - 2 주 전

EU approves Sanofi's Dupixent for 'smoker's lungs'

EU approves Sanofi's Dupixent for 'smoker's lungs' July 3 (Reuters) - Sanofi SASY.PA and partner Regeneron REGN.O on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States. The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a re
R
S
Reuters - 2 주 전

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S
Reuters - 2 주 전

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge By Brendan Pierson July 1 (Reuters) - A Delaware judge rebuffed a request by GSK GSK.L and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to go forward. The ruling by Judge Vivian Medinilla of the Delaware Superior Court means that the drugmakers, which also include Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim, will have to ask the Delaware Su
G
P
S
Reuters - 2 주 전

Sanofi eyes German insulin investment of up to $1.6 bln, source says

UPDATE 2-Sanofi eyes German insulin investment of up to $1.6 bln, source says Adds context on French politics in fourth paragraph, details on Novo Nordisk in paragraphs 8 and 9 BERLIN, July 1 (Reuters) - French drugmaker Sanofi SASY.PA is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person familiar with the plan told Reuters on Monday.
S
Reuters - 2 주 전

Sanofi eyes German insulin investment of up to $1.6 bln, source says

Sanofi eyes German insulin investment of up to $1.6 bln, source says BERLIN, July 1 (Reuters) - French drugmaker Sanofi SASY.PA is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major site in Frankfurt, Germany, to upgrade the production of long-acting insulin shots, a person familiar with the plan told Reuters on Monday.
S
Reuters - 2 주 전

Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says

UPDATE 1-Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says Adds comments by government, company in paragraphs 3 and 4 FRANKFURT, July 1 (Reuters) - French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin brand Lantus, newspaper Handelsblatt reported on Monday.
S
Reuters - 2 주 전

Scientists wary of bird flu pandemic 'unfolding in slow motion'

CORRECTED-ANALYSIS-Scientists wary of bird flu pandemic 'unfolding in slow motion' Corrects Wendy Barclay's affiliation in last paragraph By Julie Steenhuysen and Jennifer Rigby CHICAGO/LONDON, July 1 (Reuters) - Scientists tracking the spread of bird flu are increasingly concerned that gaps in surveillance may keep them several steps behind a new pandemic, according to Reuters interviews with more than a dozen leading disease experts.
G
S

조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.